Dr. Reddy’s Laboratories Ltd (NYSE:RDY) has been assigned a consensus recommendation of “Sell” from the six brokerages that are presently covering the company. Three investment analysts have rated the stock with a sell recommendation and two have given a hold recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $41.90.

RDY has been the subject of several recent research reports. TheStreet raised Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, November 14th. Zacks Investment Research raised Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, October 24th.

Dr. Reddy’s Laboratories (NYSE:RDY) opened at 43.59 on Tuesday. The stock’s 50 day moving average is $44.63 and its 200 day moving average is $45.94. Dr. Reddy’s Laboratories has a 12-month low of $41.39 and a 12-month high of $54.73. The company has a market cap of $7.22 billion, a P/E ratio of 50.69 and a beta of 0.53.

Several institutional investors have recently modified their holdings of the stock. First Mercantile Trust Co. bought a new position in shares of Dr. Reddy’s Laboratories during the third quarter valued at $158,000. Wedbush Securities Inc. bought a new position in shares of Dr. Reddy’s Laboratories during the third quarter valued at $209,000. Bayesian Capital Management LP bought a new position in shares of Dr. Reddy’s Laboratories during the fourth quarter valued at $285,000. Alps Advisors Inc. increased its position in shares of Dr. Reddy’s Laboratories by 1.0% in the third quarter. Alps Advisors Inc. now owns 7,097 shares of the company’s stock valued at $329,000 after buying an additional 67 shares during the last quarter. Finally, Wetherby Asset Management Inc. increased its position in shares of Dr. Reddy’s Laboratories by 4.9% in the fourth quarter. Wetherby Asset Management Inc. now owns 7,776 shares of the company’s stock valued at $352,000 after buying an additional 366 shares during the last quarter. Hedge funds and other institutional investors own 16.12% of the company’s stock.

“Analysts Set Dr. Reddy’s Laboratories Ltd (RDY) Price Target at $41.90” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of US and international trademark & copyright laws. The legal version of this story can be accessed at http://www.watchlistnews.com/analysts-set-dr-reddys-laboratories-ltd-rdy-price-target-at-41-90/1121623.html.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

5 Day Chart for NYSE:RDY

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.